BioSpace News Archive

Exact Sciences Corp. announced that it will present 15 abstracts at the American Society of Clinical Oncology® Annual Meeting 2023, June 2-6, in Chicago, Illinois.

Foundation Medicine, Inc., announced that the company and its collaborators will present 21 abstracts demonstrating the value of high-quality tumor profiling tests to inform cancer care at the 2023 American Society of Clinical Oncology Annual Meeting from June 2-6 in Chicago.

Positive high-level results from the DUO-E Phase III trial showed IMFINZI® in combination with platinum-based chemotherapy followed by either IMFINZI plus LYNPARZA® or IMFINZI alone as maintenance therapy both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy alone in patients with newly diagnosed advanced or recurrent endometrial cancer.

The Insight Partners published latest research report on “Intracranial Pressure (ICP) Monitoring Devices Market Size Report, Share, Trends & Growth Forecast to 2028 - COVID-19 Impact and Global Analysis By Offering, Type, Application, End User, and Geography”,

The Insight Partners published latest research study on Respiratory Care Devices Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product {Therapeutic Devices [Positive Airway Pressure (PAP) Devices (CPAP Devices, APAP Devices, and BiPAP Devices),

The Insight Partners published latest research study on “Chemotherapy-Induced Peripheral Neuropathy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class

The Insight Partners published latest research study on “Genotyping Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product and Service

According to The Insight Partners latest study on “Immunodiagnostics Market Size, Share, Growth, Trends and Forecast to 2028 – COVID-19 Impact and Global Analysis

BIOLASE, Inc. announced the closing of its previously announced underwritten public offering of 175,000 units, with each Unit consisting of one share of BIOLASE’s Series H Convertible Redeemable Preferred Stock, par value $0.001 per share, with a liquidation preference of $50.00 per share, and one warrant to purchase one-half of one share of Series H Convertible Preferred Stock.

According to the new market research report “Defibrillator Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Implantable Cardioverter Defibrillator (Transvenous ICD and Subcutaneous ICD)